Organ transplant immunosuppressant drugs are administered to prevent graft rejection in organ transplant recipients. These drugs help suppress the recipient's immune system and prevent it from attacking and rejecting the transplanted organ. The need for organ transplant procedures and immunosuppressant drugs is rising globally due to the increasing prevalence of organ failures.
The global Organ Transplant Market is estimated to be valued at US$ 5.17 Bn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The organ transplant immunosuppressant drugs market is witnessing rising demand for modified-release drugs with improved pharmacokinetic profiles. Growing incidences of late acute rejection of organ grafts are also driving development of newer small molecules and biologics. Furthermore, technological advancements in transplant techniques are allowing previously untransplantable organs to be transplanted, thus increasing demand for potent immunosuppressants as well. In addition, changing lifestyles leading to chronic illnesses are increasing numbers of organ failures, thereby fueling the organ transplant immunosuppressant drugs market growth over the forecast period.
Segment Analysis
The global organ transplant immunosuppressant drugs market is segmented into calcineurin inhibitors, anti-proliferative agents, corticosteroids, and mTOR inhibitors. Calcineurin inhibitors dominated the market and accounted for over 45% of the global market share in 2023. This is due to its high usage as the first line of treatment for organ transplant recipients owing to its high effectiveness.
Key Takeaways
The Global Organ Transplant Immunosuppressant Drugs Market Demand is expected to witness high growth, exhibiting a CAGR of 3.1% over the forecast period, due to increasing number of organ transplants globally driven by rising cases of organ failure.
Regional analysis
North America dominated the global market with over 40% share in 2023 owing to the increasing adoption of organ transplantation procedures and favorable reimbursement policies for organ transplantation in the region. Asia Pacific is expected to be the fastest growing region due to growing healthcare expenditure and increasing awareness about organ donation in countries such as China and India.
Key players analysis
Key players operating in the organ transplant immunosuppressant drugs market are Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddys Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche.
Explorer more information on this topic, Please visit -
26th September, 2018 - In the recent years, Organ Transplantation has rapidly advanced as a therapeutic interpolation that is lifesaving as well as greatly funds to a better quality of life to organ beneficiaries.
The rapid development has been made possible due to extreme growth in the immunosuppressive stock.
However, the side effects of these drugs can be severe, which is one the reasons that life expectancy of patients still considerably falls short.
They should be used only under administration of expertise.Request a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/organ-transplant-immunosuppressant-drugs-market/request-sampleAt times there may be also side-effects accompanied by immunosuppressant drugs such as increased proneness of infection, overdue wound healing, dyspepsia, etc.
The factors that propel the growth of the Organ Transplant Immunosuppressant Drug Market include rising frequency of chronic diseases, expanding number of organ donor, effective method for treatment of end-stage organ failure, high demand for organ transplant.
This consequently gives rise to a high demand for immunosuppressant drugs to avoid organ rejection after transplantation.
